Taurolock™-HEP500 in dialysis ensures superior dialysis quality and protects from infection and inflammation
In a recently published, randomised study, Ezzat et al., investigated the impact of Taurolock™-HEP500 in patients with temporary haemodialysis catheters. Based on the results of this study, the authors conclude that - compared to heparin - Taurolock™-HEP500 helps
- to achieve a lower incidence of catheter-related bloodstream infections,
- to receive a better dialysis adequacy and
- to prevent rising levels of inflammation markers, which may help to reduce the elevated mortality and morbidity of haemodialysis patients.